Ian Fleming
5Patents
2h-index
4Co-inventors
40Inventor score
Filing activity: Dec 19, 2007 → Jul 20, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8975239B2 | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine | Human Necessities | 15 | Active |
| US8349792B2 | Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent | Human Necessities | 2 | Active |
| US8530445B2 | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine | Human Necessities | 2 | Active |
| US9173938B2 | Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders | Emerging Cross-Sectional Technologies | 1 | Active |
| US11305019B2 | Functionalized nucleic acid nanostructures for RNA delivery | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.